Anyone who owns Johnson & Johnson stock (NYSE:JNJ) is along for the ride. The multinational corporation is rolling out a single-shot COVID-19 vaccine developed by its subsidiary Janssen Pharmaceuticals.
The FDA gave the Johnson & Johnson vaccine emergency use authorization on Feb. 27, after previously giving the green light to the Pfizer-BioNTech and Moderna vaccines.
“We believe the Johnson & Johnson single-shot COVID-19 vaccine is a critical tool for fighting this global pandemic, particularly as it shows protection across countries with different variants. A vaccine that protects against COVID-19, especially against the most dire outcomes of hospitalization and death, will help ease the burden on people and the strain on health systems worldwide,” Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., said in a press release.
Johnson & Johnson has gone from a family business to a “family of companies.”
Although Johnson & Johnson is having a momentous 2021, the company has been in business for well over a century. Brothers Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson founded the company in 1886 to manufacture first aid and surgical supplies. Less than a decade later, Johnson & Johnson had 400 employees, according to the company’s timeline.
Currently, Johnson & Johnson has more than 130,000 employees across a “Family of Companies” around the world, as the company explains on its website. The companies under the Johnson & Johnson banner focus on consumer health products, medical devices, and pharmaceutical products.
Top Johnson & Johnson shareholders include its CEO and EVPs.
Getting back to the people who own Johnson & Johnson stock, Investopedia listed the top five individual shareholders in JNJ stock in October 2020. Those five people are CEO Alex Gorsky, Executive Vice President Joaquin Duato, the aforementioned Stoffles, EVP Jennifer Taubert, and EVP Joseph J. Wolk.
The top institutional holders include The Vanguard Group, BlackRock, State Street Corporation, Geode Capital Management, and Wellington Management Company, according to Yahoo! Finance.
Johnson & Johnson plans to make 100 million vaccines for the U.S. in the first half of 2021.
In its press release, Johnson & Johnson said that it plans to deliver 100 million of its single-shot vaccines to the U.S. during the first six months of 2021. “We are thankful for the efforts of all those who have volunteered to participate in our clinical trials, our scientists, collaborators, clinical trial sites and investigators,” said Mathai Mammen, M.D., Ph.D., Global Head of Janssen Research & Development for Johnson & Johnson. “Through the combined commitment of everyone involved, we have been able to discover, develop and manufacture a single-shot COVID-19 vaccine to protect people around the world,”
According to Fox Business, Johnson & Johnson is scheduled to produce 1 billion doses of its COVID-19 vaccine for global distribution by the end of the year. The vaccine is expected to generate up to $10 billion for the company. Johnson & Johnson has agreed to produce up to 300 million vaccines for the U.S. and up to 400 million for the European Union.